Sharekhan

Sai Life Science Ltd

Fri 22/05/2026,15:59:32 | NSE : SAILIFE

₹ 1113.80-24.30 (-2.14%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1138.10

Previous Close

₹ 1138.10

Volume

180729

Mkt Cap ( Rs. Cr)

₹23625.43

High

₹ 1138.10

Low

₹ 1102.00

52 Week High

₹ 1153.30

52 Week Low

₹ 707.00

Book Value Per Share

₹ 111.75

Dividend Yield

0.00

Face Value

₹ 1.00

What’s Your Call?

Collective community sentiment on Sai Life Science Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

1113.80

1528

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

1528

Option Chain

Analyzes market sentiment, predicts Sai Life Science Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Sai Life Science - Analysts/Institutional Investor Meet/Con. Call Updates

    21 May 2026, 2:13PM Sai Life Sciences Limited has informed the Exchange about Transcript of Earnings Call for the Audited Financial Results of the Company for the quarter
  • Sai Life Science - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    21 May 2026, 2:11PM Transcript of Earnings Call for the Audited Financial Results for the quarter and year ended 31 March 2026.
  • Sai Life Science - Copy of Newspaper Publication

    16 May 2026, 7:12PM Sai Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication for the Audited Financial Results for the quarter and year end
  • Sai Life Science - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    15 May 2026, 7:14PM Recording of Earnings Call for the Audited Financial Results for the quarter and year ended 31 March 2026.
  • Sai Life Science - Analysts/Institutional Investor Meet/Con. Call Updates

    15 May 2026, 7:07PM Sai Life Sciences Limited has informed the Exchange about Link of Recording
  • Sai Life Science - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    15 May 2026, 3:03PM Allotment of 92,000 Equity Shares under ESOP Schemes of the Company.
  • Sai Life Science - ESOP/ESOS/ESPS

    15 May 2026, 2:57PM Sai Life Sciences Limited has informed the Exchange regarding Allotment of 92000 Shares under ESOP Schemes of the Company.
  • Sai Life Science - Monitoring Agency Report

    15 May 2026, 2:40PM Monitoring Agency Report for the quarter and year ended 31 March 2026
  • Sai Life Science - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    15 May 2026, 2:40PM Monitoring Agency Report for the quarter and year ended 31 March 2026.
  • Sai Life Science - Investor Presentation

    15 May 2026, 2:25PM Sai Life Sciences Limited has informed the Exchange about Investor Presentation
  • Sai Life Science - Announcement under Regulation 30 (LODR)-Investor Presentation

    15 May 2026, 2:24PM Investor Presentation for the quarter and year ended 31 March 2026.
  • Sai Life Science Q4 net profit up 14.00% at Rs 102.53 cr

    15 May 2026, 9:30AM The company reported standalone net profit of Rs 102.53 crore for the quarter ended March 31, 2026 as compared to Rs 89.94 crore in the same period la
  • Sai Life Science - Updates

    14 May 2026, 11:40PM Sai Life Sciences Limited has informed the Exchange regarding 'Disclosure of Key Performance Indicators under SEBI (Issue of Capital and Disclosure Re
  • Sai Life Science - Disclosure Of Key Performance Indicators Under SEBI (Issue Of Capital And Disclosure Requirements) Regulat

    14 May 2026, 11:40PM Please refer to the attached intimation.
  • Sai Life Science - Disclosure Of Key Performance Indicators Under SEBI (Issue Of Capital And Disclosure Requirements) Regulat

    14 May 2026, 11:38PM Please refer to the attached intimation.
  • Sai Life Science - Press Release

    14 May 2026, 11:29PM Sai Life Sciences Limited has informed the Exchange regarding a press release dated May 14, 2026, titled ""Press release for the Financial Results for
  • Sai Life Science - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    14 May 2026, 11:27PM Press Release for the Financial Results for the quarter and year ended 31 March 2026.
  • Sai Life Science - Audited Financial Results For The Year Ended 31 March 2026

    14 May 2026, 11:10PM Audited Financial Results for the year ended 31 March, 2026
  • Sai Life Science - Outcome of Board Meeting

    14 May 2026, 10:59PM Sai Life Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
  • Sai Life Science - Board Meeting Outcome for Board Meeting Outcome For Approval Of Audited Financial Results For The Financi

    14 May 2026, 10:56PM Considered and Approved the Audited Financial Results for the Financial Year ended 31st March, 2026.
  • Sai Life Science - Press Release

    11 May 2026, 4:46PM Sai Life Sciences Limited has informed the Exchange regarding a press release dated May 11, 2026, titled ""Achievement of 100% Renewable Power at Bida
  • Sai Life Science - Analysts/Institutional Investor Meet/Con. Call Updates

    11 May 2026, 11:32AM Earnings conference call invite for the quarter and year ended Financial Results ended on 31 March, 2026
  • Sai Life Science - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    11 May 2026, 4:50PM Intimation for Achievement of 100% renewal Power at Bidar Campus of the Company.
  • Sai Life Science - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    11 May 2026, 11:29AM Earnings conference call invite for the quarter and year ended Financial Results ended on 31 March, 2026
  • Sai Life Science - Intimation Of An Order Dated 29Th April 2026 Issued By The Joint Commissioner Of Commercial Taxes (Appeals

    30 Apr 2026, 8:35AM Please refer to the enclosed intimation.
  • Sai Life Science - Action(s) initiated or orders passed

    30 Apr 2026, 8:35AM Intimation of an Order dated 29th April 2026 issued by the Joint Commissioner of Commercial Taxes (Appeals), Kalaburagi u/s 107 (11) of the Central Go
  • Sai Life Science - ESOP/ESOS/ESPS

    23 Apr 2026, 9:36PM Sai Life Sciences Limited has informed the Exchange regarding Allotment of 244281 Shares under ESOP Schemes of the Company.
  • Sai Life Science - Board Meeting Intimation for Consideration And Approval Of Audited Financial Results (Standalone & Consoli

    21 Apr 2026, 1:53PM Sai Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider an
  • Sai Life Science has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026

    14 Apr 2026, 6:41PM As of March 2026, 34.61% is owned by Promoters and 65.39% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 32.95% and Fore
  • Sai Life Science - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    8 Apr 2026, 4:27PM Sai Life Sciences Limited has informed the Exchange about Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations,
  • Sai Life Science - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    8 Apr 2026, 4:26PM Please refer to the enclosed Intimation.
  • Sai Life Science - Change in Management

    30 Mar 2026, 10:26PM Sai Life Sciences Limited has informed the Exchange about appointment of Dr. John Pavey, Head Global PR&D as a Senior Management Personnel ( SMP ) o
  • Sai Life Science - Trading Window

    30 Mar 2026, 3:07PM Sai Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations
  • Sai Life Science - ESOP/ESOS/ESPS

    24 Mar 2026, 1:01PM Sai Life Sciences Limited has informed the Exchange regarding Allotment of 11,100 Equity Shares under ESOP 2008 Scheme of the Company.
  • Sai Life Science - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    24 Mar 2026, 12:54PM Allotment of 11,100 Equity Shares under ESOP 2008 Scheme of the Company.
  • Sai Life Science - Intimation Of An Order Dated 18Th March, 2026 Passed By The Deputy Commissioner Of Income Tax (Internation

    21 Mar 2026, 12:26PM Please refer enclosed intimation.
  • Sai Life Science - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    7 Mar 2026, 11:13AM Schedule of meeting with analyst / Investor on March 13, 2026, at Hyderabad
  • Sai Life Science - Analysts/Institutional Investor Meet/Con. Call Updates

    7 Mar 2026, 11:08AM Sai Life Sciences Limited has informed the Exchange about Schedule of meet
  • Sai Life Science - Announcement under Regulation 30 (LODR)-Credit Rating

    26 Feb 2026, 5:15PM Credit Rating Letter issued by ICRA Limited.
  • Sai Life Science - Credit Rating- New

    26 Feb 2026, 5:12PM Sai Life Sciences Limited has informed the Exchange about Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements Regu
  • Sai Life Science - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    26 Feb 2026, 4:06PM Revised Intimation for allotment of 139007 shares under ESOP Schemes of the Company.
  • Sai Life Science - ESOP/ESOS/ESPS

    26 Feb 2026, 3:59PM Sai Life Sciences Limited has informed the Exchange regarding revised Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Allotment
  • Sai Life Sciences in CMC partnership with AgilityLife & CentrixPh

    8 Oct 2025 , 1:25PM Sai Life Sciences in CMC partnership with AgilityLife & CentrixPh to accelerating drug development for innovator biopharma cos
  • Sai Life Science

    19 Sep 2025 , 12:03PM Sai Life Sciences : The Contract Research, Development, and Manufacturing Organization (CRDMO) firm, has opened near Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs.
  • Sai life sciences

    26 Aug 2025 , 11:13AM Sai life sciences: TPG Asia VII SF is expected to exit the company by selling its entire 14.72 per cent stake, comprising of 3.07 crore equity shares, through block deals. The offer size is estimated at Rs.2,500 crore, with a floor price of Rs.860 per share implying a discount of 5% on CMP. Negative

Key fundamentals

Evaluate the intrinsic value of Sai Life Science Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 2603.093 2296.1 1721.361 1611.961 1642.3565
Liabilities 2603.093 2296.1 1721.361 1611.961 1642.3565
Equity 21.178 20.841 17.663 17.623 17.5563
Gross Profit 599.957 390.446 286.61 163.141 121.3909
Net Profit 341.481 173.462 95.231 24.237 15.6826
Cash From Operating Activities 495.269 330.351 250.642 221.474 88.3798
NPM(%) 15.85 10.56 6.71 2.09 1.86
Revenue 2153.226 1642.048 1418.682 1157.403 841.0228
Expenses 1553.269 1251.602 1132.072 994.262 719.6319
ROE(%) 14.4 7.31 4.01 1.02 0.66

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Sai Life Science Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 705.80 -0.07 0.00 635.01 -26.19 0.71
Lotus Eye Hospital and Institute Ltd 109.19 1.26 352.23 2313.90 3.55 0.00
Vaishali Pharma Ltd 7.00 0.14 0.00 14515.87 3.13 0.00
Astec Lifesciences Ltd 771.80 4.77 0.00 2182.06 -363.15 0.00

Company Info

Our Company was originally incorporated as `Sai Dru Syn Laboratories Limited' at Hyderabad, Telangana (erstwhile Andhra Pradesh) as a public limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated January 25, 1999, issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. Our Company received the certificate of commencement of business from Registrar of Companies, Andhra Pradesh at Hyderabad on February 17, 1999. Subsequently, the name of our Company was changed from `Sai Dru Syn Laboratories Limited' to `Sai Life Sciences Limited' pursuant to a Shareholders' resolution in an extraordinary general meeting held on December 11, 2003 and a fresh certificate of incorporation dated December 16, 2003 consequent to change of name was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. Thereafter, the name of the Company was changed from `Sai Life Sciences Limited' to `Sai Advantium Pharma Limited' pursuant to a Shareholders' resolution in an extraordinary general meeting held on August 16, 2006 and a fresh certificate of incorporation dated August 30, 2006 consequent to change of name was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, the name of our Company was changed from `Sai Advantium Pharma Limited' to its present name, `Sai Life Sciences Limited' pursuant to a Shareholders' resolution in an extraordinary general meeting held on April 20, 2012 and a fresh certificate of incorporation dated May 28, 2012 consequent to change of name was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad.Major Events and Milestones:1999- Incorporation of our Company2002- Inauguration of our R&D labs in ICICI Knowledge Park, Hyderabad.2004- Strategic acquisitions of Prasad Drugs Limited, the current Unit III Bolarum Facility2006- Investment by Advantium LLC in our Company to set-up discovery services to expand our Company's business.- Acquired Merrifield Pharma Private Limited2007- Acquisition of shares of our Company held by Advantium LLC by Sequoia Capital India Investments III2008- Investment by MPM Investment Mauritius in our Company2014- Acquisition of shares of our Company held by MPM Investment Mauritius and Sequoia Capital India Investment III by Tata Capital Healthcare Fund 12016- Acquisition of shares of our Company held by MPM Investment Mauritius by HBM Private Equity India and subscription to shares of our Company2019- Opened biology facility in Watertown (Greater Boston, MA) U.S.A2020- Launched Sai Nxt, an initiative aiming to transform the organization into a new generation CDMO- Addition of cellular analysis platforms at our discovery biology facility in Cambridge, Massachusetts, USA2021- Opened new 75,000 sq. ft. discovery biology facility at our integrated R&D campus at Unit II Hyderabad Facility2022- Inauguration of the first set of new discovery chemistry labs as part of the new integrated discovery block at Unit II Hyderabad Facility- Announced the launch of BIOVIA Electronic Lab Notebook application. 2022 -Sai Life Sciences inks strategic agreement to set up Schr”dinger's first dedicated offshore Research Laboratories in India. -Sai Life Sciences wins National Award for Excellence in Energy Management for the third consecutive year. 2023 - Inauguration of high potency API manufacturing block at Unit IV Bidar Facility. -Sai Life Sciences wins Gold in Brandon Hall Group's Excellence in Technology Awards. 2024 - Initiated API developability & formulations (D&F) capabilities at Unit II Hyderabad. -Sai Life Sciences completes restoration of historic Manchirevula stepwell. 2025-The Company Informed Opening of Unit VI, a dedicated facility for Veterinary API production in Bidar, India.

Our Company was originally incorporated as `Sai Dru Syn Laboratories Limited' at Hyderabad, Telangana (erstwhile Andhra Pradesh) as a public limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated January 25, 1999, issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. Our Company received the certificate of commencement of business from Registrar of Companies, Andhra Pradesh at Hyderabad on February 17, 1999. Subsequently, the name of our Company was changed from `Sai Dru Syn Laboratories Limited' to `Sai Life Sciences Limited' pursuant to a Shareholders' resolution in an extraordinary general meeting held on December 11, 2003 and a fresh certificate of incorporation dated December 16, 2003 consequent to change of name was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. Thereafter, the name of the Company was changed from `Sai Life Sciences Limited' to `Sai Advantium Pharma Limited' pursuant to a Shareholders' resolution in an extraordinary general meeting held on August 16, 2006 and a fresh certificate of incorporation dated August 30, 2006 consequent to change of name was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, the name of our Company was changed from `Sai Advantium Pharma Limited' to its present name, `Sai Life Sciences Limited' pursuant to a Shareholders' resolution in an extraordinary general meeting held on April 20, 2012 and a fresh certificate of incorporation dated May 28, 2012 consequent to change of name was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad.Major Events and Milestones:1999- Incorporation of our Company2002- Inauguration of our R&D labs in ICICI Knowledge Park, Hyderabad.2004- Strategic acquisitions of Prasad Drugs Limited, the current Unit III Bolarum Facility2006- Investment by Advantium LLC in our Company to set-up discovery services to expand our Company's business.- Acquired Merrifield Pharma Private Limited2007- Acquisition of shares of our Company held by Advantium LLC by Sequoia Capital India Investments III2008- Investment by MPM Investment Mauritius in our Company2014- Acquisition of shares of our Company held by MPM Investment Mauritius and Sequoia Capital India Investment III by Tata Capital Healthcare Fund 12016- Acquisition of shares of our Company held by MPM Investment Mauritius by HBM Private Equity India and subscription to shares of our Company2019- Opened biology facility in Watertown (Greater Boston, MA) U.S.A2020- Launched Sai Nxt, an initiative aiming to transform the organization into a new generation CDMO- Addition of cellular analysis platforms at our discovery biology facility in Cambridge, Massachusetts, USA2021- Opened new 75,000 sq. ft. discovery biology facility at our integrated R&D campus at Unit II Hyderabad Facility2022- Inauguration of the first set of new discovery chemistry labs as part of the new integrated discovery block at Unit II Hyderabad Facility- Announced the launch of BIOVIA Electronic Lab Notebook application. 2022 -Sai Life Sciences inks strategic agreement to set up Schr”dinger's first dedicated offshore Research Laboratories in India. -Sai Life Sciences wins National Award for Excellence in Energy Management for the third consecutive year. 2023 - Inauguration of high potency API manufacturing block at Unit IV Bidar Facility. -Sai Life Sciences wins Gold in Brandon Hall Group's Excellence in Technology Awards. 2024 - Initiated API developability & formulations (D&F) capabilities at Unit II Hyderabad. -Sai Life Sciences completes restoration of historic Manchirevula stepwell. 2025-The Company Informed Opening of Unit VI, a dedicated facility for Veterinary API production in Bidar, India.

Parent Organisation

Sai Life Science Ltd.

Founded

25/01/1999

Managing Director

Mr.Krishnam Raju Kanumuri

NSE Symbol

SAILIFEEQ

FAQ

OPEN FREE* DEMAT ACCOUNT